바이오시밀러 시장 기회, 성장요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Biosimilars Market was valued at USD 38.7 billion in 2025 and is estimated to grow at a CAGR of 16.6% to reach USD 185.2 billion by 2035.

Strong market growth is driven by the rising demand for affordable biologic therapies and the increasing prevalence of chronic and complex medical conditions worldwide. The growing incidence of long-term diseases requiring biologic treatment solutions is significantly accelerating biosimilar adoption across healthcare systems. Biosimilars are biologic medicines developed to closely match approved reference biologics in terms of safety, effectiveness, and quality while offering more cost-efficient treatment alternatives. These therapies are playing an increasingly important role in improving patient access to advanced biologic treatments and reducing the financial burden associated with long-term disease management. Extensive clinical assessments, analytical studies, and regulatory evaluations are required to establish therapeutic equivalence and biosimilarity with originator biologics. Expanding awareness among healthcare professionals and patients, favorable reimbursement frameworks, increasing product approvals, and broader acceptance of biosimilar therapies across multiple therapeutic areas are further contributing to rapid market expansion throughout the forecast period.

The Recombinant Glycosylated Proteins segment reached USD 26.2 billion in 2025. This segment continues to hold a substantial share of the industry due to increasing demand for advanced biologic therapies utilized in the treatment of chronic and severe medical conditions. Recombinant glycosylated proteins are manufactured using advanced recombinant DNA technologies that enable accurate protein development and essential molecular modifications required for therapeutic effectiveness. Growing adoption of these biologic therapies across various disease management applications is supporting continued segment expansion. Increasing investments in biologic drug development and rising demand for cost-effective therapeutic alternatives are also strengthening growth within this category.

The hematology segment accounted for a share of 29.8% in 2025. Market growth within hematology applications is primarily driven by the increasing prevalence of blood-related disorders and rising demand for affordable biologic treatment solutions. Biosimilars are being increasingly adopted for the management of hematologic conditions due to growing confidence in their clinical performance, safety standards, and therapeutic effectiveness. Rising awareness among healthcare providers regarding the economic and clinical benefits associated with biosimilar therapies is further supporting broader utilization across hematology treatment settings. Expanding access to biologic treatment alternatives is also contributing to the segment's sustained market growth.

North America Biosimilars Market held 29.9% share in 2025 and is expected to grow at a CAGR of 16.5% during 2026-2035. The region continues to experience strong biosimilar adoption supported by increasing healthcare expenditures, growing preference for lower-cost biologic treatment options, and ongoing patent expirations for several major biologic products. North America benefits from a highly structured regulatory environment that supports efficient approval pathways and strengthens confidence in biosimilar utilization among healthcare professionals and patients. Growing pressure on healthcare systems to reduce treatment costs, along with favorable reimbursement policies and formulary optimization strategies, is accelerating biosimilar adoption across multiple therapeutic applications throughout the region.

Key companies operating in the Global Biosimilars Market include Biocon, Sandoz, Bio-Thera Solutions, Pfizer, Dr. Reddy's Laboratories, Amgen, Teva Pharmaceuticals, Fresenius Kabi, Coherus Biosciences, Apobiologix, Biocad, Intas Pharma, Celltrion, Zydus Cadila, and Samsung Bioepis. Companies operating in the biosimilars market are adopting multiple strategic initiatives to strengthen their competitive position and expand global market presence. Leading industry participants are investing heavily in research and development activities to accelerate biosimilar product launches and improve manufacturing capabilities. Strategic partnerships, licensing agreements, and collaborations with biotechnology firms are enabling companies to expand product portfolios and enhance market reach across various therapeutic areas. Organizations are also focusing on strengthening regulatory compliance and obtaining approvals across international markets to improve commercialization opportunities. Increasing investments in advanced manufacturing technologies, supply chain optimization, and biologics production facilities are further supporting long-term growth strategies. In addition, companies are prioritizing physician education programs, patient awareness initiatives, and competitive pricing strategies to increase biosimilar acceptance and strengthen their foothold within the global biosimilars industry.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 3600 synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product trends
  • 2.2.3 Application trends
  • 2.2.4 Manufacturing type trends
  • 2.2.5 Technology trends
  • 2.2.6 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising chronic disease burden
    • 3.2.1.2 Increasing biologics patent expirations
    • 3.2.1.3 Higher clinician and patient acceptance
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Limited market penetration in some regions
    • 3.2.2.2 High development and manufacturing costs
  • 3.2.3 Market opportunities
    • 3.2.3.1 Advancement in AI-driven bioprocessing
    • 3.2.3.2 Adoption of streamlined regulatory pathways
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by primary research)
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 MEA
• 3.5 Technology landscape
  • 3.5.1 Current technology
  • 3.5.2 Emerging technologies
• 3.6 Reimbursement landscape
  • 3.6.1 U.S.
  • 3.6.2 Canada
  • 3.6.3 Europe
  • 3.6.4 Australia
  • 3.6.5 New Zealand
• 3.7 Biosimilar Litigation landscape
• 3.8 Future market trends (Driven by primary research)
• 3.9 Impact of AI and generative AI on the market (Driven by primary research)
• 3.10 Biosimilars factor analysis
  • 3.10.1 Access
  • 3.10.2 Regulations
  • 3.10.3 Payer assessment and access
  • 3.10.4 Physician acceptance
  • 3.10.5 Patient acceptance
• 3.11 Biosimilar product pipeline analysis
• 3.12 Biosimilars approval scenario, 2022 - 2025
• 3.13 Biologics patent expiry scenario
• 3.14 International policies on use of biosimilar drugs
  • 3.14.1 Interchangeability, switching and subsitution
  • 3.14.2 Supply side policies
  • 3.14.3 Prescribing incentives
• 3.15 Porter's analysis
• 3.16 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2022-2035 ($ Mn)

• 5.1 Key trends
• 5.2 Recombinant non-glycosylated proteins
  • 5.2.1 Human growth hormone
  • 5.2.2 Granulocyte colony-stimulating factor (filgrastim)
  • 5.2.3 Insulin
  • 5.2.4 Interferon
    • 5.2.4.1 Alfa
    • 5.2.4.2 Beta
• 5.3 Recombinant glycosylated proteins
  • 5.3.1 Monoclonal antibodies
    • 5.3.1.1 Infliximab
    • 5.3.1.2 Rituximab
    • 5.3.1.3 Adalimumab
    • 5.3.1.4 Trastuzumab
    • 5.3.1.5 Bevacizumab
  • 5.3.2 Erythropoietin
    • 5.3.2.1 Alfa
    • 5.3.2.2 Beta
  • 5.3.3 Follitropin
    • 5.3.3.1 Alfa
    • 5.3.3.2 Beta
  • 5.3.4 Fusion proteins
• 5.4 Other products

Chapter 6 Market Estimates and Forecast, By Application, 2022-2035 ($ Mn)

• 6.1 Key trends
• 6.2 Hematology
  • 6.2.1 Neutropenia
  • 6.2.2 Anemia
  • 6.2.3 Other hematology applications
• 6.3 Oncology
  • 6.3.1 Lung cancer
  • 6.3.2 Brain cancer
  • 6.3.3 Breast cancer
  • 6.3.4 Cervical cancer
  • 6.3.5 Colorectal cancer
  • 6.3.6 Leukemia
  • 6.3.7 Other Oncology applications
• 6.4 Autoimmune disease
  • 6.4.1 Arthritis
    • 6.4.1.1 Rheumatoid arthritis
    • 6.4.1.2 Psoriatic arthritis
    • 6.4.1.3 Juvenile arthritis
    • 6.4.1.4 Ankylosing spondylitis
    • 6.4.1.5 Other arthritis
  • 6.4.2 Inflammatory bowel disease (IBD)
    • 6.4.2.1 Ulcerative colitis
    • 6.4.2.2 Crohn's disease
    • 6.4.2.3 Other IBD
  • 6.4.3 Psoriasis
  • 6.4.4 Other autoimmune diseases
• 6.5 Ophthalmology
• 6.6 Growth hormone deficiency
• 6.7 Diabetes
• 6.8 Other applications

Chapter 7 Market Estimates and Forecast, By Manufacturing Type, 2022-2035 ($ Mn)

• 7.1 Key trends
• 7.2 Contract research and manufacturing services
• 7.3 In-house

Chapter 8 Market Estimates and Forecast, By Technology, 2022-2035 ($ Mn)

• 8.1 Key trends
• 8.2 Recombinant DNA technology
• 8.3 Mammalian cell culture systems
• 8.4 Other technologies

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2022-2035 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Specialty pharmacies
• 9.4 Other distribution channels

Chapter 10 Market Estimates and Forecast, By Region, 2022-2035 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Biocon
• 11.2 Sandoz
• 11.3 Bio-Thera Solutions
• 11.4 Pfizer
• 11.5 Dr. Reddy’s Laboratories
• 11.6 Amgen
• 11.7 Teva Pharmaceuticals
• 11.8 Fresenius Kabi
• 11.9 Coherus Biosciences
• 11.10 Apobiologix
• 11.11 Biocad
• 11.12 Intas Pharma
• 11.13 Celltrion
• 11.14 Zydus Cadila
• 11.15 Samsung Bioepis